Subscribe
  
IPQ Inside the global regulatory dialogue

Design-Based Development Paradigm for Cell/Gene Therapies Will Significantly Reduce Costs, Timelines and Regulatory Concerns, AGT CEO Galvin Affirms

Aug 27th, 2020

Please Log in to print the full article

Manufacturing and Testing Demands Are Reduced Galvin then explained how reduced manufacturing costs flow from the ability to make the CGT materials in bioreactors that can be reused for different projects and not having to...

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2020 IPQ Publications